Guardant Health, Inc. Stock News

Guardant Health, Inc. (NASDAQ:GH ) Analyst/Investor Day September 24, 2025 9:00 AM EDT Company Participants Zarak Khurshid - Vice President of Investor Relations Helmy Eltoukhy - Co-Founder, Co-CEO & Chairman AmirAli Talasaz - Co-CEO & Director Darya Chudova - Chief Technology Officer Craig Eagle - Chief Medical Officer Christopher Freeman - Chief Commercial Officer of Oncology Jaime Boyle - Se...

PALO ALTO, Calif. & SECAUCUS, N.J.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced a broad strategic collaboration to make Guardant's Shield™ blood-based screening test available to physicians and patients served by Quest in the United States. Shiel...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the appointment of Alex M. Azar II to its board of directors, effective immediately. As the 24th Secretary of the U.S. Department of Health and Human Services (HHS), Secretary Azar had oversight and management of agencies critical to all Americans' health care including ...

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it has reached a strategic agreement with LabFlorida/SunDx Labs to provide residents of senior living communities access to Guardant Shield™, the first blood test approved by the U.S. Food and Drug Administration (FDA) as a primary screening option for colorectal...

Guardant Health, Inc. (NASDAQ:GH ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 4:05 PM EDT Company Participants Helmy Eltoukhy - Co-Founder, Co-CEO & Chairman AmirAli Talasaz - Co-CEO & Director Michael Bell - Chief Financial Officer Conference Call Participants Kallum Titchmarsh - Morgan Stanley, Research Division Presentation Kallum Titchmarsh Equity Analyst Okay...

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a strategic partnership with PathGroup, one of the nation's leading partners to physicians, hospitals, and healthcare networks nationwide, to significantly expand the reach of Guardant's FDA-approved Shield™ blood test. The partnership will bring Shield to more t...

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a positive clinical readout update assessing the performance of the latest colorectal cancer (CRC) screening algorithm (V2) for its Shield™ blood test. The study met all primary endpoints and the sensitivity of this new screening algorithm for detecting CRC was 8...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be hosting an Investor Day on September 24, 2025, in New York City, NY starting at 9:00 a.m. Eastern Time / 6:00 a.m. Pacific Time. The event will feature presentations by several members of the company's leadership team. Interested parties may access a ...